Look for studies on ClinicalTrials.gov, PubMed, or major medical journals like The New England Journal of Medicine
GIP improves insulin sensitivity, may influence fat tissue metabolism directly, and appears to amplify the appetite-suppressing effects of GLP-1 in ways researchers are still mapping
Retatrutide at 12 mg weekly currently produces the largest weight loss of any published Phase 3 GLP-1-class compound, exceeding tirzepatide (22.5% in SURMOUNT-1) and semaglutide (14.9% in STEP-1) at comparable timepoints
Future direction The evolution of GLP-1RAs is increasingly shifting toward oral formulations, aiming to enhance patient adherence by eliminating the need for injections and addressing the logistical complexities associated with traditional peptide therapies [72, 73]
A comprehensive medication review is critical to identify drugs that may contribute to blood pressure reduction, including antihypertensives, alpha-blockers, tricyclic antidepressants, and certain medications for benign prostatic hyperplasia
Retatrutide may represent the next generation of weight loss medications but as of now, its not approved, not legal, and not safe for consumer use in the UK